Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32
Authors:
Open Access
- 15 July 2011
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 18 (9) , 663-673
Abstract
Interleukin-32 (IL-32) is a pro-inflammatory cytokine conditionally produced by T cells, natural killer (NK) cells, monocytes, epithelial cells and keratinocytes, which has an important role in host resistance against infectious disease. Interestingly, elevated levels of IL-32 transcripts in fine needle aspirates of tumor tissue have also been correlated with objective clinical responses in cancer patients receiving immunotherapy. To evaluate the antitumor impact of IL-32 gene therapy, we treated BALB/c mice bearing established subcutaneous CMS4 sarcomas with intratumoral (i.t.) injections of syngenic dendritic cells (DCs) engineered to express human IL-32β complementary DNA (that is, DC.IL32). Although ectopic expression of IL-32β by DC resulted in only modest phenotypic changes in these antigen-presenting cells, DC.IL32 produced higher levels of IL-12p70 than control DC. DC.IL32 were more potent activators of type-1 T-cell responses in vitro and in vivo, with i.t. administration of DC.IL32 leading to the CD8+ T-cell-dependent (but CD4+ T-cell- and NK cell-independent) suppression of tumor growth. Effective DC.IL32-based therapy promoted infiltration of tumors by type-1 (that is, CXCR3+VLA-4+GrB+) CD8+ T cells and CD11b+CD11c+ host myeloid DC, but led to reductions in the prevalence of CD11b+Gr1+ myeloid-derived suppressor cells and CD31+ blood vessels.Keywords
This publication has 50 references indexed in Scilit:
- Inflammation-dependent secretion and splicing of IL-32γ in rheumatoid arthritisProceedings of the National Academy of Sciences, 2011
- Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expressionof interleukin-32 controls the expression of the humanpapillomavirus oncogeneImmunology, 2011
- Interleukin-32 Expression in the PancreasJournal of Biological Chemistry, 2009
- Molecular characterization of IL-32 in human endothelial cellsCytokine, 2009
- Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunityCancer Gene Therapy, 2009
- Welcome to the neighborhood: epithelial cell‐derived cytokines license innate and adaptive immune responses at mucosal sitesImmunological Reviews, 2008
- CD8+ T-Cell Responses against Hemoglobin-β Prevent Solid Tumor GrowthCancer Research, 2008
- Interleukin-32 induces the differentiation of monocytes into macrophage-like cellsProceedings of the National Academy of Sciences, 2008
- Epithelial overexpression of interleukin-32α in inflammatory bowel diseaseClinical and Experimental Immunology, 2007
- IL-32: An Emerging Player in the Immune Response Network against Tuberculosis?PLOS Medicine, 2006